<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01761578</url>
  </required_header>
  <id_info>
    <org_study_id>ARTDIVA</org_study_id>
    <nct_id>NCT01761578</nct_id>
  </id_info>
  <brief_title>ARTDIVA Study : First in Man Safety Evaluation of the ART18Z Bioresorbable Stent</brief_title>
  <official_title>First in Man Safety Evaluation of the ART18Z Bioresorbable Stent for the Treatment of Single de Novo Lesion of a Native Coronary Artery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arterial Remodeling Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arterial Remodeling Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multicentre, open labeled, single arm, first in man interventional&#xD;
      investigation aims to evaluate the safety of the ART18Z bioresorbable stent for the treatment&#xD;
      of patients with single de novo lesion of a native coronary artery with mandatory balloon&#xD;
      predilatation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE rate</measure>
    <time_frame>at 6 months</time_frame>
    <description>Major Adverse Cardiac Event is defined as death, MI (Myocardial Infarction) or any TLR (Target Lesion Revascularization).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Performances (Device/Procedure Success)</measure>
    <time_frame>Procedure and post-procedure up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>at 1, 3, 6, 12, 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven TVF, TLR, TVR</measure>
    <time_frame>at 1, 3, 6, 12, 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Angiographic binary restenosis</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Angiographic in-stent Late Lumen Loss</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of stent coverage by OCT</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the neointima by OCT</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>ART18Z Bioresorbable stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ART18Z Bioresorbable stent</intervention_name>
    <description>The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.</description>
    <arm_group_label>ART18Z Bioresorbable stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility:&#xD;
&#xD;
        - Healthy voluntary and women of child-bearing potential are not accepted&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
        Target lesion must meet all of the following criteria&#xD;
&#xD;
          -  Single vessel lesion&#xD;
&#xD;
          -  De novo lesion&#xD;
&#xD;
          -  Located in a native coronary artery with visually estimated nominal artery diameter of&#xD;
             2.8 to 3.2 mm&#xD;
&#xD;
          -  Length ≤ 8 mm visually estimated&#xD;
&#xD;
          -  Located in a major artery or branch with a visually estimated stenosis &gt;50% and &lt;100%&#xD;
             with a TIMI flow ≥1&#xD;
&#xD;
        General Inclusion Criteria:&#xD;
&#xD;
        Patient profile:&#xD;
&#xD;
          -  Patient is able to verbally confirm understanding of risks, benefits and treatment&#xD;
             alternatives of receiving the ART18Z Bioresorbable Stent.&#xD;
&#xD;
          -  Patient provides written informed consent approved by the EC prior to any clinical&#xD;
             investigation related procedure&#xD;
&#xD;
          -  Patient must agree to undergo all clinical investigation plan - required clinical&#xD;
             follow-up visits, QCA, OCT&#xD;
&#xD;
          -  Patient must agree not to participate in any other clinical investigation for a period&#xD;
             of 3 years following the procedure&#xD;
&#xD;
          -  a social security number is required, otherwise patients cannot be included in the&#xD;
             trial.&#xD;
&#xD;
        Clinical profile:&#xD;
&#xD;
          -  Silent ischemia, stable or unstable angina with documented ischemia (stress&#xD;
             echocardiography, 12-lead ECG, nuclear imaging, bicycle test, Treadmill stress test)&#xD;
&#xD;
          -  3 months limited clopidogrel treatment must be acceptable in compliance with patient&#xD;
             health status&#xD;
&#xD;
          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)&#xD;
             surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
          -  Target lesion meets any of the following criteria:&#xD;
&#xD;
          -  Aorto-ostial location (within 3 mm)&#xD;
&#xD;
          -  Left main location&#xD;
&#xD;
          -  located within 3 mm of the origin of the LAD or LCX&#xD;
&#xD;
          -  Located within an arterial or saphenous vein graft or distal to a diseased (defined as&#xD;
             vessel irregularity per angiogram and &gt;20% stenosed lesion, by visual estimation)&#xD;
             arterial or saphenous vein graft&#xD;
&#xD;
          -  Lesion involving a bifurcation ≥ 1.5 mm in diameter and ostial lesion &gt; 40% stenosed&#xD;
             by visual estimation or side branch requiring predilatation&#xD;
&#xD;
          -  Excessive tortuosity proximal to or within the lesion (Extreme angulation (≥ 90%)&#xD;
             proximal)&#xD;
&#xD;
          -  Calcification lesion&#xD;
&#xD;
          -  Restenotic from previous intervention&#xD;
&#xD;
          -  The target vessel contains visible thrombus&#xD;
&#xD;
          -  Chronic total occlusion (CTO)&#xD;
&#xD;
          -  Another clinically significant lesion is located in the same major epicardial vessel&#xD;
             as the target lesion (including side branches)&#xD;
&#xD;
          -  Patient has a high probability that a procedure other than pre-dilatation and stenting&#xD;
             will be required at the time of procedure for treatment of the target vessel (e.g.&#xD;
             atherectomy, cutting balloon)&#xD;
&#xD;
          -  Non clinical investigation percutaneous intervention in the target vessel &lt; 6 months&#xD;
             prior to or if planned to be done within 6 months after the investigational procedure.&#xD;
&#xD;
          -  Non clinical investigation percutaneous intervention in a non-target vessel &lt; 1 months&#xD;
             prior to the investigational procedure with TIMI flow = 3 and no evidence of&#xD;
             dissection at the time of the clinical investigation procedure, or if planned to be&#xD;
             done within 6 months after the investigational procedure.&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
          -  Evidence of an acute MI within 3 weeks of the intended investigational procedure&#xD;
&#xD;
          -  Patient has current unstable arrhythmias&#xD;
&#xD;
          -  Patient has a known left ventricular ejection fraction (LVEF) &lt; 30%&#xD;
&#xD;
          -  Patient has received a heart transplant or any other organ transplant or is on a&#xD;
             waiting list for any organ transplant&#xD;
&#xD;
          -  Patient is receiving or scheduled to receive chemotherapy for malignancy within 30&#xD;
             days prior to or after the procedure&#xD;
&#xD;
          -  Patient is receiving immunosuppression therapy and has known immunosuppressive or&#xD;
             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus&#xD;
             etc.)&#xD;
&#xD;
          -  Patient is receiving or scheduled to receive chronic anticoagulation therapy (e.g.,&#xD;
             heparin, coumadin)&#xD;
&#xD;
          -  Patient has a known hypersensitivity or contraindication to aspirin, both heparin and&#xD;
             bivalirudin, both clopidogrel and ticlopidine, or contrast sensitivity that cannot be&#xD;
             adequately pre-medicated&#xD;
&#xD;
          -  Elective surgery is planned within the first 6 months after the procedure that will&#xD;
             require discontinuing either aspirin or clopidogrel&#xD;
&#xD;
          -  Patient has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a WBC of &lt;&#xD;
             3,000 cells/mm3, or documented or suspected liver disease (including laboratory&#xD;
             evidence of hepatitis)&#xD;
&#xD;
          -  Patient has known renal insufficiency with creatine clearance &lt; 40 ml/min or patient&#xD;
             on dialysis&#xD;
&#xD;
          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood&#xD;
             transfusions&#xD;
&#xD;
          -  Patient has had a cerebro vascular accident (CVA) or transient ischemic neurological&#xD;
             attack (TIA) within the past six months&#xD;
&#xD;
          -  Patient has had a significant GI or urinary bleed within the past six months&#xD;
&#xD;
          -  Patient has extensive peripheral vascular disease that precludes safe 6 French sheath&#xD;
             insertion&#xD;
&#xD;
          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known&#xD;
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause&#xD;
             non-compliance with the clinical investigation plan, confound the data interpretation&#xD;
             or is associated with a &lt; 24 months limited life expectancy&#xD;
&#xD;
          -  Vulnerable population (refer to §6.4)&#xD;
&#xD;
          -  Patient is already participating in another clinical investigation that has not yet&#xD;
             reached its primary endpoint&#xD;
&#xD;
          -  Pregnant or nursing patients and those who plan pregnancy during the clinical&#xD;
             investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Polyclinique les Fleurs</name>
      <address>
        <city>Ollioules</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.art-stent.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioresorbable</keyword>
  <keyword>Coronary</keyword>
  <keyword>Stent</keyword>
  <keyword>Vascular Remodeling</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

